Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
16. August 2015 20:28 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
06. August 2014 20:57 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Mesoblast Accelerates Plans For Commercialization Manufacturing Operations In Singapore
27. Mai 2014 23:10 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 27, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it is bringing forward plans for its...
Mesoblast, Intrexon and ZIOPHARM to Target Cancers
23. Oktober 2013 18:28 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB), a world leader in the development of cell-based biologic products, Intrexon Corporation (NYSE: XON),...
Mesoblast's Strong Cash Position Enables Execution of Late-Stage Clinical Trials
29. August 2013 00:42 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 29, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY), today provided its full year financial results. The...
Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy
25. Juni 2013 21:12 ET
|
Mesoblast
NEW YORK, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- Key Points:∙ Mesoblast has received ethics approvals to begin a clinical trial of its proprietary allogeneic, or “off-the-shelf”,...